{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-23-000003","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.620018+00:00","generated_at":"2026-06-20T18:29:53.316650+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Aspira Women's Health reports Q4 2022 preliminary volumes up 18%; expects $6M cost savings","bullets":["Q4 2022 OvaSuite test volume 5,643 (+18% YoY); full-year 2022 volume 21,424 (+23% YoY).","Achieved previously provided Q4 cash utilization guidance of $6-8 million.","Anticipates ~$6M in cost savings from staff reductions; does not expect material impact on growth.","Expanded territories for top field reps; optimizing BioReference co-marketing agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-23-000003","json":"https://secwatch.observer/filing/0000926617-23-000003.json","markdown":"https://secwatch.observer/filing/0000926617-23-000003.md","text":"https://secwatch.observer/filing/0000926617-23-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/0000926617-23-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/awh-20230109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:29:53.316650+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8e84dc8e4810ba998ca6b3e7f92a8250aeb0315e","claim":"Aspira Women's Health Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).","evidence_excerpt":"Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/0000926617-23-000003-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"bc76cf4e0fb035e7b18cd4a4df8510c089169eab","claim":"Aspira Women's Health Inc. updated its the three months ended December 31, 2021 guidance (reaffirmed).","evidence_excerpt":"Aspira Women's Health Inc. issued a press release announcing certain operational metrics for the fourth quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661723000003/0000926617-23-000003-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended December 31, 2021"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}